nodes	percent_of_prediction	percent_of_DWPC	metapath
Dicyclomine—CYP1A1—lung cancer	0.57	1	CbGaD
Dicyclomine—CYP1A1—Gefitinib—lung cancer	0.11	0.628	CbGbCtD
Dicyclomine—CYP1A1—Erlotinib—lung cancer	0.0653	0.371	CbGbCtD
Dicyclomine—Immune system disorder—Docetaxel—lung cancer	0.000223	0.00112	CcSEcCtD
Dicyclomine—Headache—Erlotinib—lung cancer	0.000223	0.00112	CcSEcCtD
Dicyclomine—Loss of consciousness—Paclitaxel—lung cancer	0.000223	0.00112	CcSEcCtD
Dicyclomine—Diplopia—Doxorubicin—lung cancer	0.000222	0.00112	CcSEcCtD
Dicyclomine—Mediastinal disorder—Docetaxel—lung cancer	0.000222	0.00111	CcSEcCtD
Dicyclomine—Paraesthesia—Gemcitabine—lung cancer	0.000222	0.00111	CcSEcCtD
Dicyclomine—Asthenia—Vinorelbine—lung cancer	0.00022	0.00111	CcSEcCtD
Dicyclomine—Decreased appetite—Irinotecan—lung cancer	0.00022	0.0011	CcSEcCtD
Dicyclomine—Dyspnoea—Gemcitabine—lung cancer	0.00022	0.0011	CcSEcCtD
Dicyclomine—Nausea—Vinblastine—lung cancer	0.00022	0.0011	CcSEcCtD
Dicyclomine—Somnolence—Gemcitabine—lung cancer	0.000219	0.0011	CcSEcCtD
Dicyclomine—Anorexia—Cisplatin—lung cancer	0.000219	0.0011	CcSEcCtD
Dicyclomine—Affect lability—Doxorubicin—lung cancer	0.000219	0.0011	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Irinotecan—lung cancer	0.000219	0.0011	CcSEcCtD
Dicyclomine—Hypertension—Paclitaxel—lung cancer	0.000219	0.0011	CcSEcCtD
Dicyclomine—Fatigue—Irinotecan—lung cancer	0.000218	0.0011	CcSEcCtD
Dicyclomine—Pruritus—Vinorelbine—lung cancer	0.000217	0.00109	CcSEcCtD
Dicyclomine—Discomfort—Etoposide—lung cancer	0.000217	0.00109	CcSEcCtD
Dicyclomine—Pain—Irinotecan—lung cancer	0.000217	0.00109	CcSEcCtD
Dicyclomine—Constipation—Irinotecan—lung cancer	0.000217	0.00109	CcSEcCtD
Dicyclomine—Mental disorder—Docetaxel—lung cancer	0.000216	0.00108	CcSEcCtD
Dicyclomine—Face oedema—Doxorubicin—lung cancer	0.000215	0.00108	CcSEcCtD
Dicyclomine—Erythema—Docetaxel—lung cancer	0.000215	0.00108	CcSEcCtD
Dicyclomine—Decreased appetite—Gemcitabine—lung cancer	0.000215	0.00108	CcSEcCtD
Dicyclomine—Nausea—Topotecan—lung cancer	0.000213	0.00107	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000213	0.00107	CcSEcCtD
Dicyclomine—Discomfort—Paclitaxel—lung cancer	0.000213	0.00107	CcSEcCtD
Dicyclomine—Fatigue—Gemcitabine—lung cancer	0.000213	0.00107	CcSEcCtD
Dicyclomine—Confusional state—Etoposide—lung cancer	0.000212	0.00107	CcSEcCtD
Dicyclomine—Pain—Gemcitabine—lung cancer	0.000211	0.00106	CcSEcCtD
Dicyclomine—Constipation—Gemcitabine—lung cancer	0.000211	0.00106	CcSEcCtD
Dicyclomine—Nausea—Erlotinib—lung cancer	0.000211	0.00106	CcSEcCtD
Dicyclomine—Dry mouth—Paclitaxel—lung cancer	0.000211	0.00106	CcSEcCtD
Dicyclomine—Anaphylactic shock—Etoposide—lung cancer	0.000211	0.00106	CcSEcCtD
Dicyclomine—Mood swings—Doxorubicin—lung cancer	0.000211	0.00106	CcSEcCtD
Dicyclomine—Feeling abnormal—Irinotecan—lung cancer	0.000209	0.00105	CcSEcCtD
Dicyclomine—Confusional state—Paclitaxel—lung cancer	0.000208	0.00105	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Irinotecan—lung cancer	0.000207	0.00104	CcSEcCtD
Dicyclomine—Anaphylactic shock—Paclitaxel—lung cancer	0.000207	0.00104	CcSEcCtD
Dicyclomine—Oedema—Paclitaxel—lung cancer	0.000207	0.00104	CcSEcCtD
Dicyclomine—Paraesthesia—Cisplatin—lung cancer	0.000207	0.00104	CcSEcCtD
Dicyclomine—Tachycardia—Etoposide—lung cancer	0.000206	0.00103	CcSEcCtD
Dicyclomine—Dyspnoea—Cisplatin—lung cancer	0.000205	0.00103	CcSEcCtD
Dicyclomine—Erectile dysfunction—Methotrexate—lung cancer	0.000204	0.00103	CcSEcCtD
Dicyclomine—Feeling abnormal—Gemcitabine—lung cancer	0.000203	0.00102	CcSEcCtD
Dicyclomine—Shock—Paclitaxel—lung cancer	0.000203	0.00102	CcSEcCtD
Dicyclomine—Dizziness—Vinorelbine—lung cancer	0.000203	0.00102	CcSEcCtD
Dicyclomine—Nervous system disorder—Paclitaxel—lung cancer	0.000203	0.00102	CcSEcCtD
Dicyclomine—Tachycardia—Paclitaxel—lung cancer	0.000202	0.00101	CcSEcCtD
Dicyclomine—Breast disorder—Doxorubicin—lung cancer	0.000201	0.00101	CcSEcCtD
Dicyclomine—Anorexia—Etoposide—lung cancer	0.000201	0.00101	CcSEcCtD
Dicyclomine—Abdominal pain—Irinotecan—lung cancer	0.0002	0.001	CcSEcCtD
Dicyclomine—Decreased appetite—Cisplatin—lung cancer	0.0002	0.001	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Cisplatin—lung cancer	0.000199	0.000996	CcSEcCtD
Dicyclomine—Drowsiness—Methotrexate—lung cancer	0.000198	0.000993	CcSEcCtD
Dicyclomine—Anorexia—Paclitaxel—lung cancer	0.000197	0.000988	CcSEcCtD
Dicyclomine—Pain—Cisplatin—lung cancer	0.000197	0.000987	CcSEcCtD
Dicyclomine—Muscular weakness—Doxorubicin—lung cancer	0.000196	0.000984	CcSEcCtD
Dicyclomine—Vomiting—Vinorelbine—lung cancer	0.000195	0.00098	CcSEcCtD
Dicyclomine—Rash—Vinorelbine—lung cancer	0.000194	0.000972	CcSEcCtD
Dicyclomine—Dermatitis—Vinorelbine—lung cancer	0.000194	0.000971	CcSEcCtD
Dicyclomine—Abdominal distension—Doxorubicin—lung cancer	0.000193	0.000971	CcSEcCtD
Dicyclomine—Headache—Vinorelbine—lung cancer	0.000192	0.000966	CcSEcCtD
Dicyclomine—Syncope—Docetaxel—lung cancer	0.000192	0.000966	CcSEcCtD
Dicyclomine—Palpitations—Docetaxel—lung cancer	0.00019	0.000951	CcSEcCtD
Dicyclomine—Feeling abnormal—Cisplatin—lung cancer	0.00019	0.000951	CcSEcCtD
Dicyclomine—Paraesthesia—Etoposide—lung cancer	0.000189	0.000949	CcSEcCtD
Dicyclomine—Loss of consciousness—Docetaxel—lung cancer	0.000189	0.000946	CcSEcCtD
Dicyclomine—Dyspnoea—Etoposide—lung cancer	0.000188	0.000943	CcSEcCtD
Dicyclomine—Somnolence—Etoposide—lung cancer	0.000187	0.00094	CcSEcCtD
Dicyclomine—Insomnia—Paclitaxel—lung cancer	0.000187	0.000938	CcSEcCtD
Dicyclomine—Hypersensitivity—Irinotecan—lung cancer	0.000187	0.000937	CcSEcCtD
Dicyclomine—Paraesthesia—Paclitaxel—lung cancer	0.000186	0.000931	CcSEcCtD
Dicyclomine—Hypertension—Docetaxel—lung cancer	0.000185	0.00093	CcSEcCtD
Dicyclomine—Dyspnoea—Paclitaxel—lung cancer	0.000184	0.000924	CcSEcCtD
Dicyclomine—Somnolence—Paclitaxel—lung cancer	0.000184	0.000922	CcSEcCtD
Dicyclomine—Decreased appetite—Etoposide—lung cancer	0.000183	0.000919	CcSEcCtD
Dicyclomine—Nausea—Vinorelbine—lung cancer	0.000182	0.000915	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Etoposide—lung cancer	0.000182	0.000913	CcSEcCtD
Dicyclomine—Dyspepsia—Paclitaxel—lung cancer	0.000182	0.000913	CcSEcCtD
Dicyclomine—Asthenia—Irinotecan—lung cancer	0.000182	0.000912	CcSEcCtD
Dicyclomine—Fatigue—Etoposide—lung cancer	0.000182	0.000912	CcSEcCtD
Dicyclomine—Constipation—Etoposide—lung cancer	0.00018	0.000904	CcSEcCtD
Dicyclomine—Pain—Etoposide—lung cancer	0.00018	0.000904	CcSEcCtD
Dicyclomine—Decreased appetite—Paclitaxel—lung cancer	0.00018	0.000901	CcSEcCtD
Dicyclomine—Dry mouth—Docetaxel—lung cancer	0.000179	0.000896	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000178	0.000895	CcSEcCtD
Dicyclomine—Fatigue—Paclitaxel—lung cancer	0.000178	0.000894	CcSEcCtD
Dicyclomine—Asthenia—Gemcitabine—lung cancer	0.000177	0.000888	CcSEcCtD
Dicyclomine—Constipation—Paclitaxel—lung cancer	0.000177	0.000887	CcSEcCtD
Dicyclomine—Pain—Paclitaxel—lung cancer	0.000177	0.000887	CcSEcCtD
Dicyclomine—Confusional state—Docetaxel—lung cancer	0.000177	0.000886	CcSEcCtD
Dicyclomine—Oedema—Docetaxel—lung cancer	0.000175	0.000879	CcSEcCtD
Dicyclomine—Anaphylactic shock—Docetaxel—lung cancer	0.000175	0.000879	CcSEcCtD
Dicyclomine—Pruritus—Gemcitabine—lung cancer	0.000175	0.000876	CcSEcCtD
Dicyclomine—Feeling abnormal—Etoposide—lung cancer	0.000174	0.000871	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Etoposide—lung cancer	0.000172	0.000865	CcSEcCtD
Dicyclomine—Shock—Docetaxel—lung cancer	0.000172	0.000865	CcSEcCtD
Dicyclomine—Nervous system disorder—Docetaxel—lung cancer	0.000172	0.000862	CcSEcCtD
Dicyclomine—Drowsiness—Doxorubicin—lung cancer	0.000171	0.00086	CcSEcCtD
Dicyclomine—Tachycardia—Docetaxel—lung cancer	0.000171	0.000858	CcSEcCtD
Dicyclomine—Feeling abnormal—Paclitaxel—lung cancer	0.00017	0.000854	CcSEcCtD
Dicyclomine—Hypersensitivity—Cisplatin—lung cancer	0.000169	0.00085	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Paclitaxel—lung cancer	0.000169	0.000848	CcSEcCtD
Dicyclomine—Dizziness—Irinotecan—lung cancer	0.000168	0.000841	CcSEcCtD
Dicyclomine—Urticaria—Etoposide—lung cancer	0.000167	0.00084	CcSEcCtD
Dicyclomine—Anorexia—Docetaxel—lung cancer	0.000167	0.000838	CcSEcCtD
Dicyclomine—Abdominal pain—Etoposide—lung cancer	0.000167	0.000836	CcSEcCtD
Dicyclomine—Eye disorder—Methotrexate—lung cancer	0.000166	0.000833	CcSEcCtD
Dicyclomine—Asthenia—Cisplatin—lung cancer	0.000165	0.000828	CcSEcCtD
Dicyclomine—Cardiac disorder—Methotrexate—lung cancer	0.000165	0.000827	CcSEcCtD
Dicyclomine—Urticaria—Paclitaxel—lung cancer	0.000164	0.000824	CcSEcCtD
Dicyclomine—Abdominal pain—Paclitaxel—lung cancer	0.000163	0.00082	CcSEcCtD
Dicyclomine—Vomiting—Irinotecan—lung cancer	0.000161	0.000808	CcSEcCtD
Dicyclomine—Immune system disorder—Methotrexate—lung cancer	0.00016	0.000805	CcSEcCtD
Dicyclomine—Mediastinal disorder—Methotrexate—lung cancer	0.00016	0.000803	CcSEcCtD
Dicyclomine—Rash—Irinotecan—lung cancer	0.00016	0.000801	CcSEcCtD
Dicyclomine—Dermatitis—Irinotecan—lung cancer	0.00016	0.000801	CcSEcCtD
Dicyclomine—Headache—Irinotecan—lung cancer	0.000159	0.000796	CcSEcCtD
Dicyclomine—Insomnia—Docetaxel—lung cancer	0.000158	0.000795	CcSEcCtD
Dicyclomine—Paraesthesia—Docetaxel—lung cancer	0.000157	0.000789	CcSEcCtD
Dicyclomine—Vomiting—Gemcitabine—lung cancer	0.000157	0.000787	CcSEcCtD
Dicyclomine—Dyspnoea—Docetaxel—lung cancer	0.000156	0.000783	CcSEcCtD
Dicyclomine—Somnolence—Docetaxel—lung cancer	0.000156	0.000781	CcSEcCtD
Dicyclomine—Mental disorder—Methotrexate—lung cancer	0.000156	0.000781	CcSEcCtD
Dicyclomine—Rash—Gemcitabine—lung cancer	0.000156	0.000781	CcSEcCtD
Dicyclomine—Dermatitis—Gemcitabine—lung cancer	0.000155	0.00078	CcSEcCtD
Dicyclomine—Hypersensitivity—Etoposide—lung cancer	0.000155	0.000779	CcSEcCtD
Dicyclomine—Erythema—Methotrexate—lung cancer	0.000155	0.000776	CcSEcCtD
Dicyclomine—Headache—Gemcitabine—lung cancer	0.000155	0.000776	CcSEcCtD
Dicyclomine—Dyspepsia—Docetaxel—lung cancer	0.000154	0.000773	CcSEcCtD
Dicyclomine—Hypoaesthesia—Doxorubicin—lung cancer	0.000153	0.000768	CcSEcCtD
Dicyclomine—Decreased appetite—Docetaxel—lung cancer	0.000152	0.000764	CcSEcCtD
Dicyclomine—Hypersensitivity—Paclitaxel—lung cancer	0.000152	0.000764	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Docetaxel—lung cancer	0.000151	0.000759	CcSEcCtD
Dicyclomine—Asthenia—Etoposide—lung cancer	0.000151	0.000759	CcSEcCtD
Dicyclomine—Fatigue—Docetaxel—lung cancer	0.000151	0.000758	CcSEcCtD
Dicyclomine—Nausea—Irinotecan—lung cancer	0.00015	0.000755	CcSEcCtD
Dicyclomine—Pain—Docetaxel—lung cancer	0.00015	0.000751	CcSEcCtD
Dicyclomine—Constipation—Docetaxel—lung cancer	0.00015	0.000751	CcSEcCtD
Dicyclomine—Pruritus—Etoposide—lung cancer	0.000149	0.000748	CcSEcCtD
Dicyclomine—Asthenia—Paclitaxel—lung cancer	0.000148	0.000744	CcSEcCtD
Dicyclomine—Nausea—Gemcitabine—lung cancer	0.000147	0.000735	CcSEcCtD
Dicyclomine—Vomiting—Cisplatin—lung cancer	0.000146	0.000734	CcSEcCtD
Dicyclomine—Pruritus—Paclitaxel—lung cancer	0.000146	0.000733	CcSEcCtD
Dicyclomine—Vision blurred—Methotrexate—lung cancer	0.000146	0.000731	CcSEcCtD
Dicyclomine—Rash—Cisplatin—lung cancer	0.000145	0.000728	CcSEcCtD
Dicyclomine—Dermatitis—Cisplatin—lung cancer	0.000145	0.000727	CcSEcCtD
Dicyclomine—Feeling abnormal—Docetaxel—lung cancer	0.000144	0.000724	CcSEcCtD
Dicyclomine—Eye disorder—Doxorubicin—lung cancer	0.000144	0.000721	CcSEcCtD
Dicyclomine—Ill-defined disorder—Methotrexate—lung cancer	0.000144	0.00072	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Docetaxel—lung cancer	0.000143	0.000719	CcSEcCtD
Dicyclomine—Cardiac disorder—Doxorubicin—lung cancer	0.000143	0.000716	CcSEcCtD
Dicyclomine—Malaise—Methotrexate—lung cancer	0.000139	0.0007	CcSEcCtD
Dicyclomine—Dizziness—Etoposide—lung cancer	0.000139	0.000699	CcSEcCtD
Dicyclomine—Immune system disorder—Doxorubicin—lung cancer	0.000139	0.000697	CcSEcCtD
Dicyclomine—Mediastinal disorder—Doxorubicin—lung cancer	0.000139	0.000696	CcSEcCtD
Dicyclomine—Abdominal pain—Docetaxel—lung cancer	0.000138	0.000695	CcSEcCtD
Dicyclomine—Dizziness—Paclitaxel—lung cancer	0.000137	0.000686	CcSEcCtD
Dicyclomine—Nausea—Cisplatin—lung cancer	0.000137	0.000686	CcSEcCtD
Dicyclomine—Mental disorder—Doxorubicin—lung cancer	0.000135	0.000676	CcSEcCtD
Dicyclomine—Vomiting—Etoposide—lung cancer	0.000134	0.000672	CcSEcCtD
Dicyclomine—Erythema—Doxorubicin—lung cancer	0.000134	0.000672	CcSEcCtD
Dicyclomine—Rash—Etoposide—lung cancer	0.000133	0.000667	CcSEcCtD
Dicyclomine—Dermatitis—Etoposide—lung cancer	0.000133	0.000666	CcSEcCtD
Dicyclomine—Headache—Etoposide—lung cancer	0.000132	0.000662	CcSEcCtD
Dicyclomine—Tension—Doxorubicin—lung cancer	0.000131	0.000659	CcSEcCtD
Dicyclomine—Vomiting—Paclitaxel—lung cancer	0.000131	0.000659	CcSEcCtD
Dicyclomine—Rash—Paclitaxel—lung cancer	0.00013	0.000654	CcSEcCtD
Dicyclomine—Dermatitis—Paclitaxel—lung cancer	0.00013	0.000653	CcSEcCtD
Dicyclomine—Discomfort—Methotrexate—lung cancer	0.00013	0.000653	CcSEcCtD
Dicyclomine—Nervousness—Doxorubicin—lung cancer	0.00013	0.000653	CcSEcCtD
Dicyclomine—Headache—Paclitaxel—lung cancer	0.000129	0.000649	CcSEcCtD
Dicyclomine—Hypersensitivity—Docetaxel—lung cancer	0.000129	0.000647	CcSEcCtD
Dicyclomine—Confusional state—Methotrexate—lung cancer	0.000127	0.000639	CcSEcCtD
Dicyclomine—Anaphylactic shock—Methotrexate—lung cancer	0.000126	0.000633	CcSEcCtD
Dicyclomine—Vision blurred—Doxorubicin—lung cancer	0.000126	0.000633	CcSEcCtD
Dicyclomine—Asthenia—Docetaxel—lung cancer	0.000126	0.00063	CcSEcCtD
Dicyclomine—Nausea—Etoposide—lung cancer	0.000125	0.000628	CcSEcCtD
Dicyclomine—Ill-defined disorder—Doxorubicin—lung cancer	0.000124	0.000623	CcSEcCtD
Dicyclomine—Pruritus—Docetaxel—lung cancer	0.000124	0.000622	CcSEcCtD
Dicyclomine—Nervous system disorder—Methotrexate—lung cancer	0.000124	0.000621	CcSEcCtD
Dicyclomine—Agitation—Doxorubicin—lung cancer	0.000123	0.000617	CcSEcCtD
Dicyclomine—Nausea—Paclitaxel—lung cancer	0.000123	0.000616	CcSEcCtD
Dicyclomine—Malaise—Doxorubicin—lung cancer	0.000121	0.000606	CcSEcCtD
Dicyclomine—Anorexia—Methotrexate—lung cancer	0.00012	0.000604	CcSEcCtD
Dicyclomine—Syncope—Doxorubicin—lung cancer	0.00012	0.000603	CcSEcCtD
Dicyclomine—Palpitations—Doxorubicin—lung cancer	0.000118	0.000594	CcSEcCtD
Dicyclomine—Loss of consciousness—Doxorubicin—lung cancer	0.000118	0.000591	CcSEcCtD
Dicyclomine—Dizziness—Docetaxel—lung cancer	0.000116	0.000581	CcSEcCtD
Dicyclomine—Hypertension—Doxorubicin—lung cancer	0.000116	0.00058	CcSEcCtD
Dicyclomine—Insomnia—Methotrexate—lung cancer	0.000114	0.000573	CcSEcCtD
Dicyclomine—Paraesthesia—Methotrexate—lung cancer	0.000113	0.000569	CcSEcCtD
Dicyclomine—Discomfort—Doxorubicin—lung cancer	0.000113	0.000565	CcSEcCtD
Dicyclomine—Dyspnoea—Methotrexate—lung cancer	0.000113	0.000565	CcSEcCtD
Dicyclomine—Somnolence—Methotrexate—lung cancer	0.000112	0.000563	CcSEcCtD
Dicyclomine—Dry mouth—Doxorubicin—lung cancer	0.000112	0.000559	CcSEcCtD
Dicyclomine—Vomiting—Docetaxel—lung cancer	0.000111	0.000559	CcSEcCtD
Dicyclomine—Dyspepsia—Methotrexate—lung cancer	0.000111	0.000557	CcSEcCtD
Dicyclomine—Rash—Docetaxel—lung cancer	0.00011	0.000554	CcSEcCtD
Dicyclomine—Dermatitis—Docetaxel—lung cancer	0.00011	0.000554	CcSEcCtD
Dicyclomine—Confusional state—Doxorubicin—lung cancer	0.00011	0.000553	CcSEcCtD
Dicyclomine—Decreased appetite—Methotrexate—lung cancer	0.00011	0.000551	CcSEcCtD
Dicyclomine—Headache—Docetaxel—lung cancer	0.00011	0.00055	CcSEcCtD
Dicyclomine—Anaphylactic shock—Doxorubicin—lung cancer	0.000109	0.000548	CcSEcCtD
Dicyclomine—Oedema—Doxorubicin—lung cancer	0.000109	0.000548	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Methotrexate—lung cancer	0.000109	0.000547	CcSEcCtD
Dicyclomine—Fatigue—Methotrexate—lung cancer	0.000109	0.000546	CcSEcCtD
Dicyclomine—Pain—Methotrexate—lung cancer	0.000108	0.000542	CcSEcCtD
Dicyclomine—Shock—Doxorubicin—lung cancer	0.000108	0.00054	CcSEcCtD
Dicyclomine—Nervous system disorder—Doxorubicin—lung cancer	0.000107	0.000538	CcSEcCtD
Dicyclomine—Tachycardia—Doxorubicin—lung cancer	0.000107	0.000535	CcSEcCtD
Dicyclomine—Anorexia—Doxorubicin—lung cancer	0.000104	0.000523	CcSEcCtD
Dicyclomine—Nausea—Docetaxel—lung cancer	0.000104	0.000522	CcSEcCtD
Dicyclomine—Feeling abnormal—Methotrexate—lung cancer	0.000104	0.000522	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Methotrexate—lung cancer	0.000103	0.000518	CcSEcCtD
Dicyclomine—Urticaria—Methotrexate—lung cancer	0.0001	0.000503	CcSEcCtD
Dicyclomine—Abdominal pain—Methotrexate—lung cancer	9.98e-05	0.000501	CcSEcCtD
Dicyclomine—Insomnia—Doxorubicin—lung cancer	9.89e-05	0.000496	CcSEcCtD
Dicyclomine—Paraesthesia—Doxorubicin—lung cancer	9.81e-05	0.000492	CcSEcCtD
Dicyclomine—Dyspnoea—Doxorubicin—lung cancer	9.74e-05	0.000489	CcSEcCtD
Dicyclomine—Somnolence—Doxorubicin—lung cancer	9.72e-05	0.000488	CcSEcCtD
Dicyclomine—Dyspepsia—Doxorubicin—lung cancer	9.62e-05	0.000483	CcSEcCtD
Dicyclomine—Decreased appetite—Doxorubicin—lung cancer	9.5e-05	0.000477	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Doxorubicin—lung cancer	9.44e-05	0.000473	CcSEcCtD
Dicyclomine—Fatigue—Doxorubicin—lung cancer	9.42e-05	0.000473	CcSEcCtD
Dicyclomine—Constipation—Doxorubicin—lung cancer	9.35e-05	0.000469	CcSEcCtD
Dicyclomine—Pain—Doxorubicin—lung cancer	9.35e-05	0.000469	CcSEcCtD
Dicyclomine—Hypersensitivity—Methotrexate—lung cancer	9.3e-05	0.000467	CcSEcCtD
Dicyclomine—Asthenia—Methotrexate—lung cancer	9.06e-05	0.000454	CcSEcCtD
Dicyclomine—Feeling abnormal—Doxorubicin—lung cancer	9.01e-05	0.000452	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Doxorubicin—lung cancer	8.94e-05	0.000448	CcSEcCtD
Dicyclomine—Pruritus—Methotrexate—lung cancer	8.93e-05	0.000448	CcSEcCtD
Dicyclomine—Urticaria—Doxorubicin—lung cancer	8.68e-05	0.000436	CcSEcCtD
Dicyclomine—Abdominal pain—Doxorubicin—lung cancer	8.64e-05	0.000434	CcSEcCtD
Dicyclomine—Dizziness—Methotrexate—lung cancer	8.35e-05	0.000419	CcSEcCtD
Dicyclomine—Hypersensitivity—Doxorubicin—lung cancer	8.05e-05	0.000404	CcSEcCtD
Dicyclomine—Vomiting—Methotrexate—lung cancer	8.03e-05	0.000403	CcSEcCtD
Dicyclomine—Rash—Methotrexate—lung cancer	7.96e-05	0.000399	CcSEcCtD
Dicyclomine—Dermatitis—Methotrexate—lung cancer	7.95e-05	0.000399	CcSEcCtD
Dicyclomine—Headache—Methotrexate—lung cancer	7.91e-05	0.000397	CcSEcCtD
Dicyclomine—Asthenia—Doxorubicin—lung cancer	7.84e-05	0.000393	CcSEcCtD
Dicyclomine—Pruritus—Doxorubicin—lung cancer	7.73e-05	0.000388	CcSEcCtD
Dicyclomine—Nausea—Methotrexate—lung cancer	7.5e-05	0.000376	CcSEcCtD
Dicyclomine—Dizziness—Doxorubicin—lung cancer	7.23e-05	0.000363	CcSEcCtD
Dicyclomine—Vomiting—Doxorubicin—lung cancer	6.95e-05	0.000349	CcSEcCtD
Dicyclomine—Rash—Doxorubicin—lung cancer	6.89e-05	0.000346	CcSEcCtD
Dicyclomine—Dermatitis—Doxorubicin—lung cancer	6.89e-05	0.000345	CcSEcCtD
Dicyclomine—Headache—Doxorubicin—lung cancer	6.85e-05	0.000344	CcSEcCtD
Dicyclomine—Nausea—Doxorubicin—lung cancer	6.49e-05	0.000326	CcSEcCtD
Dicyclomine—CHRM1—GPCR downstream signaling—PIK3CD—lung cancer	1.56e-05	0.000286	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PIK3CD—lung cancer	1.56e-05	0.000285	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	1.55e-05	0.000285	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—TYMS—lung cancer	1.55e-05	0.000284	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PIK3CD—lung cancer	1.54e-05	0.000283	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	1.54e-05	0.000282	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—POMC—lung cancer	1.54e-05	0.000282	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—POMC—lung cancer	1.53e-05	0.000281	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—GSTM1—lung cancer	1.53e-05	0.000281	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—POMC—lung cancer	1.52e-05	0.000278	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—STK11—lung cancer	1.51e-05	0.000277	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—STK11—lung cancer	1.51e-05	0.000276	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—IL6R—lung cancer	1.5e-05	0.000275	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—IL6R—lung cancer	1.49e-05	0.000274	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—STK11—lung cancer	1.49e-05	0.000273	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—IL6R—lung cancer	1.48e-05	0.000271	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FOXO3—lung cancer	1.46e-05	0.000267	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FOXO3—lung cancer	1.45e-05	0.000266	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CYP1A1—lung cancer	1.45e-05	0.000266	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—ERCC2—lung cancer	1.44e-05	0.000264	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FOXO3—lung cancer	1.44e-05	0.000264	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—STK11—lung cancer	1.43e-05	0.000262	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—MAP2K1—lung cancer	1.43e-05	0.000262	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—MAP2K1—lung cancer	1.42e-05	0.000261	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CD—lung cancer	1.42e-05	0.00026	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CD—lung cancer	1.41e-05	0.000259	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—MAP2K1—lung cancer	1.41e-05	0.000258	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CD—lung cancer	1.4e-05	0.000257	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—AVP—lung cancer	1.37e-05	0.00025	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—PIK3CB—lung cancer	1.36e-05	0.00025	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—AVP—lung cancer	1.36e-05	0.00025	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PIK3CB—lung cancer	1.36e-05	0.000249	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—AVP—lung cancer	1.35e-05	0.000247	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PIK3CB—lung cancer	1.34e-05	0.000246	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—lung cancer	1.34e-05	0.000246	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—GSTP1—lung cancer	1.32e-05	0.000243	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IGF1R—lung cancer	1.31e-05	0.000241	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IGF1R—lung cancer	1.31e-05	0.00024	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—CXCL8—lung cancer	1.31e-05	0.00024	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—CXCL8—lung cancer	1.3e-05	0.000239	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IGF1R—lung cancer	1.3e-05	0.000238	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—CXCL8—lung cancer	1.29e-05	0.000237	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HES1—lung cancer	1.29e-05	0.000237	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CAT—lung cancer	1.29e-05	0.000236	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HES1—lung cancer	1.29e-05	0.000236	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.28e-05	0.000235	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HES1—lung cancer	1.27e-05	0.000234	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—RAF1—lung cancer	1.27e-05	0.000232	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—RAF1—lung cancer	1.26e-05	0.000231	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ABCB1—lung cancer	1.25e-05	0.00023	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—IL2—lung cancer	1.25e-05	0.000229	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—RAF1—lung cancer	1.25e-05	0.000229	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—IL2—lung cancer	1.25e-05	0.000229	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—APOA1—lung cancer	1.25e-05	0.000228	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CB—lung cancer	1.24e-05	0.000227	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—IL2—lung cancer	1.23e-05	0.000226	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CB—lung cancer	1.23e-05	0.000226	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—TYMS—lung cancer	1.23e-05	0.000225	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CB—lung cancer	1.22e-05	0.000224	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—GSTM1—lung cancer	1.22e-05	0.000223	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CXCL8—lung cancer	1.19e-05	0.000218	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—CXCL8—lung cancer	1.18e-05	0.000217	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ERBB3—lung cancer	1.18e-05	0.000216	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ERBB3—lung cancer	1.18e-05	0.000216	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CXCL8—lung cancer	1.17e-05	0.000215	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ERBB3—lung cancer	1.17e-05	0.000214	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ERCC2—lung cancer	1.14e-05	0.00021	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CG—lung cancer	1.14e-05	0.000208	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—IL2—lung cancer	1.14e-05	0.000208	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—IL2—lung cancer	1.13e-05	0.000208	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TERT—lung cancer	1.13e-05	0.000207	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TERT—lung cancer	1.13e-05	0.000207	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—IL2—lung cancer	1.12e-05	0.000206	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TERT—lung cancer	1.12e-05	0.000205	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FGFR1—lung cancer	1.1e-05	0.000201	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FGFR1—lung cancer	1.1e-05	0.000201	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FGFR1—lung cancer	1.08e-05	0.000199	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HIF1A—lung cancer	1.08e-05	0.000198	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—POMC—lung cancer	1.08e-05	0.000198	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HIF1A—lung cancer	1.08e-05	0.000198	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HIF1A—lung cancer	1.07e-05	0.000196	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CREBBP—lung cancer	1.05e-05	0.000193	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—APOA1—lung cancer	1.04e-05	0.000191	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—APOA1—lung cancer	1.04e-05	0.000191	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KDR—lung cancer	1.04e-05	0.00019	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KDR—lung cancer	1.03e-05	0.000189	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—APOA1—lung cancer	1.03e-05	0.000189	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KDR—lung cancer	1.02e-05	0.000187	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CD—lung cancer	9.99e-06	0.000183	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—APOA1—lung cancer	9.89e-06	0.000181	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—ALB—lung cancer	9.87e-06	0.000181	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KIT—lung cancer	9.54e-06	0.000175	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CG—lung cancer	9.54e-06	0.000175	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—APC—lung cancer	9.54e-06	0.000175	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—NRAS—lung cancer	9.54e-06	0.000175	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CG—lung cancer	9.51e-06	0.000174	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KIT—lung cancer	9.51e-06	0.000174	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—APC—lung cancer	9.51e-06	0.000174	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—NRAS—lung cancer	9.51e-06	0.000174	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	9.47e-06	0.000174	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EGF—lung cancer	9.43e-06	0.000173	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KIT—lung cancer	9.41e-06	0.000173	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—APC—lung cancer	9.41e-06	0.000173	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CG—lung cancer	9.41e-06	0.000173	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—NRAS—lung cancer	9.41e-06	0.000173	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EGF—lung cancer	9.4e-06	0.000172	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EGF—lung cancer	9.3e-06	0.000171	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—MAPK3—lung cancer	9.13e-06	0.000167	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—MAPK3—lung cancer	9.1e-06	0.000167	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—POMC—lung cancer	9.08e-06	0.000166	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—POMC—lung cancer	9.05e-06	0.000166	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CG—lung cancer	9.03e-06	0.000166	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—MAPK3—lung cancer	9.01e-06	0.000165	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—BRAF—lung cancer	8.96e-06	0.000164	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—POMC—lung cancer	8.96e-06	0.000164	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—BRAF—lung cancer	8.93e-06	0.000164	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IL6R—lung cancer	8.85e-06	0.000162	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—BRAF—lung cancer	8.85e-06	0.000162	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CREBBP—lung cancer	8.84e-06	0.000162	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IL6R—lung cancer	8.83e-06	0.000162	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CREBBP—lung cancer	8.81e-06	0.000162	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IL6R—lung cancer	8.74e-06	0.00016	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CREBBP—lung cancer	8.73e-06	0.00016	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CB—lung cancer	8.71e-06	0.00016	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—EGFR—lung cancer	8.69e-06	0.000159	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—EGFR—lung cancer	8.66e-06	0.000159	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PTGS2—lung cancer	8.63e-06	0.000158	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—POMC—lung cancer	8.6e-06	0.000158	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—EGFR—lung cancer	8.58e-06	0.000157	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MAP2K1—lung cancer	8.44e-06	0.000155	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MAP2K1—lung cancer	8.41e-06	0.000154	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CD—lung cancer	8.38e-06	0.000154	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CREBBP—lung cancer	8.37e-06	0.000153	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CD—lung cancer	8.36e-06	0.000153	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MAP2K1—lung cancer	8.33e-06	0.000153	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—PIK3CA—lung cancer	8.3e-06	0.000152	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PIK3CA—lung cancer	8.28e-06	0.000152	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CD—lung cancer	8.27e-06	0.000152	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—KRAS—lung cancer	8.21e-06	0.00015	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PIK3CA—lung cancer	8.2e-06	0.00015	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—KRAS—lung cancer	8.18e-06	0.00015	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—KRAS—lung cancer	8.1e-06	0.000148	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CD—lung cancer	7.94e-06	0.000145	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ALB—lung cancer	7.84e-06	0.000144	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CA—lung cancer	7.54e-06	0.000138	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PTEN—lung cancer	7.53e-06	0.000138	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CA—lung cancer	7.52e-06	0.000138	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MDM2—lung cancer	7.51e-06	0.000138	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MDM2—lung cancer	7.49e-06	0.000137	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—RAF1—lung cancer	7.48e-06	0.000137	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—RAF1—lung cancer	7.46e-06	0.000137	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CA—lung cancer	7.44e-06	0.000136	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MDM2—lung cancer	7.41e-06	0.000136	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ERBB2—lung cancer	7.4e-06	0.000136	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—RAF1—lung cancer	7.39e-06	0.000135	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ERBB2—lung cancer	7.38e-06	0.000135	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ERBB2—lung cancer	7.31e-06	0.000134	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MTOR—lung cancer	7.31e-06	0.000134	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CB—lung cancer	7.31e-06	0.000134	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MTOR—lung cancer	7.28e-06	0.000133	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CB—lung cancer	7.28e-06	0.000133	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MTOR—lung cancer	7.21e-06	0.000132	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CB—lung cancer	7.21e-06	0.000132	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—EP300—lung cancer	7.18e-06	0.000132	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CXCL8—lung cancer	7.02e-06	0.000129	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CXCL8—lung cancer	7e-06	0.000128	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—HRAS—lung cancer	6.98e-06	0.000128	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—HRAS—lung cancer	6.95e-06	0.000127	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CXCL8—lung cancer	6.93e-06	0.000127	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CB—lung cancer	6.92e-06	0.000127	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—HRAS—lung cancer	6.89e-06	0.000126	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PTGS2—lung cancer	6.86e-06	0.000126	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—AKT1—lung cancer	6.78e-06	0.000124	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—AKT1—lung cancer	6.76e-06	0.000124	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CASP3—lung cancer	6.72e-06	0.000123	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IL2—lung cancer	6.71e-06	0.000123	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CASP3—lung cancer	6.7e-06	0.000123	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—AKT1—lung cancer	6.7e-06	0.000123	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IL2—lung cancer	6.69e-06	0.000123	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—IL6—lung cancer	6.68e-06	0.000122	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—IL6—lung cancer	6.66e-06	0.000122	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CASP3—lung cancer	6.63e-06	0.000122	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IL2—lung cancer	6.62e-06	0.000121	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—IL6—lung cancer	6.59e-06	0.000121	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CCND1—lung cancer	6.54e-06	0.00012	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—JUN—lung cancer	6.53e-06	0.00012	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CCND1—lung cancer	6.52e-06	0.00012	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—JUN—lung cancer	6.51e-06	0.000119	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CCND1—lung cancer	6.46e-06	0.000118	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—JUN—lung cancer	6.44e-06	0.000118	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MMP9—lung cancer	6.35e-06	0.000116	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MMP9—lung cancer	6.33e-06	0.000116	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CDKN1A—lung cancer	6.33e-06	0.000116	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PTEN—lung cancer	6.31e-06	0.000116	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CDKN1A—lung cancer	6.31e-06	0.000116	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PTEN—lung cancer	6.29e-06	0.000115	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MMP9—lung cancer	6.27e-06	0.000115	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CDKN1A—lung cancer	6.25e-06	0.000114	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PTEN—lung cancer	6.23e-06	0.000114	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—AKT1—lung cancer	6.16e-06	0.000113	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—AKT1—lung cancer	6.14e-06	0.000113	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—AKT1—lung cancer	6.08e-06	0.000111	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EP300—lung cancer	6.02e-06	0.00011	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EP300—lung cancer	6e-06	0.00011	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PTEN—lung cancer	5.98e-06	0.00011	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EP300—lung cancer	5.94e-06	0.000109	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SRC—lung cancer	5.86e-06	0.000107	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SRC—lung cancer	5.84e-06	0.000107	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SRC—lung cancer	5.78e-06	0.000106	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—VEGFA—lung cancer	5.7e-06	0.000105	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—EP300—lung cancer	5.7e-06	0.000105	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—VEGFA—lung cancer	5.68e-06	0.000104	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—STAT3—lung cancer	5.65e-06	0.000103	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NRAS—lung cancer	5.63e-06	0.000103	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—VEGFA—lung cancer	5.63e-06	0.000103	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—STAT3—lung cancer	5.63e-06	0.000103	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NRAS—lung cancer	5.62e-06	0.000103	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—STAT3—lung cancer	5.57e-06	0.000102	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NRAS—lung cancer	5.56e-06	0.000102	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MAPK3—lung cancer	5.39e-06	9.89e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MAPK3—lung cancer	5.38e-06	9.86e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MAPK3—lung cancer	5.33e-06	9.76e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CA—lung cancer	5.31e-06	9.73e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MYC—lung cancer	5.25e-06	9.62e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MYC—lung cancer	5.23e-06	9.59e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MYC—lung cancer	5.18e-06	9.49e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EGFR—lung cancer	5.13e-06	9.41e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EGFR—lung cancer	5.12e-06	9.38e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EGFR—lung cancer	5.07e-06	9.28e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KRAS—lung cancer	4.85e-06	8.89e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KRAS—lung cancer	4.83e-06	8.86e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KRAS—lung cancer	4.79e-06	8.77e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CA—lung cancer	4.45e-06	8.16e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CA—lung cancer	4.44e-06	8.14e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CA—lung cancer	4.4e-06	8.06e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—AKT1—lung cancer	4.34e-06	7.95e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TP53—lung cancer	4.31e-06	7.9e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TP53—lung cancer	4.3e-06	7.87e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TP53—lung cancer	4.25e-06	7.8e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CA—lung cancer	4.22e-06	7.73e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HRAS—lung cancer	4.12e-06	7.55e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HRAS—lung cancer	4.11e-06	7.53e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HRAS—lung cancer	4.07e-06	7.46e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IL6—lung cancer	3.94e-06	7.23e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IL6—lung cancer	3.93e-06	7.21e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IL6—lung cancer	3.89e-06	7.14e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—AKT1—lung cancer	3.64e-06	6.67e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—AKT1—lung cancer	3.63e-06	6.65e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—AKT1—lung cancer	3.59e-06	6.58e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—AKT1—lung cancer	3.45e-06	6.32e-05	CbGpPWpGaD
